HighTower Advisors
TRIL

HighTower Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

HighTower Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,925
Closed -$117K – 3491
2021
Q1 		$117K Buy
+10,925
New +$135K ﹤0.01% 2731

Other funds holding TRIL

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

HighTower Advisors's TRIL Position: Q2 2021 in Review

HighTower Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q2 2021, closing a stake of 10,925 shares — an estimated $117K sold.

HighTower Advisors first reported a position in TRIL in Q1 2021 and held it in 1 quarter. The position peaked at $117K in Q1 2021. 137 funds tracked by Wall St. Rank hold TRIL as of Q2 2021.

  • HighTower Advisors reported no remaining Trillium Therapeutics Inc. position as of Q2 2021 after selling out during the quarter.
  • HighTower Advisors sold 10,925 Trillium Therapeutics Inc. shares in Q2 2021, an estimated $117K.
  • HighTower Advisors first reported a position in Trillium Therapeutics Inc. in Q1 2021 and held it in 1 quarter.
  • HighTower Advisors's Trillium Therapeutics Inc. position peaked at $117K in Q1 2021.
  • 137 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q2 2021.

Based on HighTower Advisors's 13F filing for Q2 2021, filed 6 Aug 2021.